|
Metabolite
|
Receptor (Gene/Protein)
|
Potency/Affinity
|
Species & Cell Type
|
Disease Model
|
Downstream Signaling
|
Evidence Level
|
Pharmacological Tool
|
Major Limitation
|
Key Reference(s)
|
| SCFAs (acetate, propionate, butyrate) |
FFAR2/GPR43; FFAR3/GPR41 |
Propionate EC50 ~6–290 μM (assay-dependent; FFAR2/3) |
Mouse; immune cells, endothelium, VSMCs |
Ang II–induced HTN, Apoe−/− atherosclerosis |
FFAR2: Gq/Gi; FFAR3: Gi/o |
Level I–II |
4-CMTB (FFAR2 agonist-positive allosteric modulator); FFAR3 agonist (AR420626) |
Receptor redundancy; opposing BP effects of FFAR3 vs. Olfr78 |
[6,7,9,10,11,12,13,14,15,16] |
| SCFAs (propionate) |
Olfr78 (olfactory receptor) |
Propionate EC50 ~0.6–0.9 mM |
Mouse; juxtaglomerular cells, VSMCs |
BP regulation, renin secretion |
Gαolf → AC → cAMP |
Level II (KO mice) |
No selective pharmacological tool available |
Low ligand affinity; species differences in expression |
[10] |
| Butyrate |
HCAR2 |
Butyrate EC50 ~0.7–1.6 mM |
Mouse; macrophages |
Atherosclerosis |
Gi/o (↓cAMP) |
Level II–III |
Niacin (non-selective agonist) |
HCAR2 also activated by BHB; broad tissue expression |
[11,12,90,91,92,93,94,96,97,98,99] |
| Long-chain ceramides |
CYSLTR2 + P2RY6 (dual receptor) |
C16:0 ceramide EC50 ~μM range |
Mouse; macrophages, endothelium |
Atherosclerosis (Apoe−/−) |
Gq (PLC–IP3–Ca2+), NLRP3 |
Level I–II |
Dual receptor antagonists (experimental) |
Dual receptor complexity; limited human data |
[17,18,19,20] |
| Bile acids |
GPBAR1/TGR5 |
LCA EC50 ~0.5 μM; DCA ~1 μM |
Mouse/human; endothelium, VSMCs, cardiomyocytes, macrophages |
Atherosclerosis, MI, HF, HTN |
Gs (cAMP–PKA) |
Level II–III |
BAR501 (selective agonist); INT-777 (agonist, Ldlr−/− data) |
Systemic effects; gallstone risk with agonists; agonist- and model-dependent effects (BAR501/Apoe−/− vs. INT-777/Ldlr−/−) |
[21,22,23,24,25,26,27,28,29,30] |
| LPA |
LPAR1–6 |
LPA(18:1) EC50 ~1–100 nM (subtype-dependent) |
Mouse/human; monocytes, platelets, endothelium, valve cells |
Atherosclerosis, CAVD, thrombosis |
LPAR1/3: Gq/Gi |
Level II–III |
Ki16425 (LPAR1/3 antagonist); BMS-986020 (LPAR1) |
Subtype redundancy; LPA species heterogeneity |
[31,32,33,34,35,36,37] |
| PGI2 |
PTGIR/IP receptor |
PGI2 EC50 ~nM |
Human/mouse; VSMCs, platelets, endothelium |
PAH, atherosclerosis, MI |
Gs (cAMP) |
Level I (clinical drugs) |
Epoprostenol, treprostinil, selexipag |
Short half-life; systemic vasodilation |
[38,41,42,43,44] |
| PGE2 |
PTGER1–4/EP1–EP4 |
PGE2 EC50 ~nM (subtype-dependent) |
Mouse; cardiomyocytes, fibroblasts, immune cells |
MI, ventricular remodeling |
EP3: Gi; EP4: Gs |
Level II |
EP3 antagonist (DG-041); EP4 agonist (CAY10580) |
Subtype-specific opposing effects |
[38,39] |
| TXA2 |
TBXA2R/TP receptor |
TXA2 analog U46619 EC50 ~nM |
Human/mouse; platelets, VSMCs |
Thrombosis, vasospasm |
Gq/G12/13 |
Level I (aspirin, upstream COX inhibition) |
SQ29548 (antagonist) |
TXA2 instability; upstream COX inhibition used clinically |
[40,41] |
| LTB4 |
LTB4R/BLT1; LTB4R2/BLT2 |
LTB4 EC50 ~0.1–1 nM (BLT1) |
Mouse/human; neutrophils, monocytes, macrophages, VSMCs |
Atherosclerosis, MI |
BLT1: Gi; BLT2: Gq/Gi |
Level II–III |
CP-105,696 (BLT1 antagonist) |
Limited clinical cardiovascular outcomes data |
[45,46,47,49] |
| Cysteinyl LTs (LTC4/D4/E4) |
CYSLTR1/CysLT1; CYSLTR2/CysLT2 |
LTD4 EC50 ~0.4–1 nM (CysLT1) |
Human/mouse; endothelium, VSMCs, macrophages, platelets |
Atherosclerosis, ischemia |
CysLT1: Gq; CysLT2: Gq/Gi |
Level II–III |
Montelukast, zafirlukast (CysLT1 antagonists) |
Approved for asthma only; no cardiovascular outcomes trials |
[45,46,48,49] |
| Anandamide (AEA), 2-AG |
CNR1/CB1; CNR2/CB2 |
AEA Ki ~60–540 nM (CB1), ~280–1940 nM (CB2); 2-AG Ki ~60–470 nM (CB1), ~150–1400 nM (CB2) |
Human/mouse; endothelium, VSMCs, cardiomyocytes, macrophages |
Atherosclerosis, MI, HF, shock |
CB1: Gi/o; CB2: Gi/o |
Level II–III |
JD5037 (peripheral CB1 antagonist); HU-308 (CB2 agonist) |
CB1 central side effects; CB2 context-dependent effects |
[50,51,52,53,54] |
| Kynurenic acid (KynA) |
GPR35 |
KynA EC50 ~40 μM (human GPR35) |
Human/mouse; macrophages, lymphatic endothelial cells |
MI, atrial fibrillation |
Gi/o (β-arrestin) |
Level I–III |
Zaprinast (agonist); pamoic acid (agonist) |
Low potency; species differences (human GPR35 requires higher kynurenic acid concentrations than rodent orthologs; EC50 ~40 μM vs. ~7–11 μM) |
[64,65,66,67,68,69,70,71,72,73,74,114] |
| GABA |
GABBR1/GABBR2 heterodimer (GABAB receptor) |
GABA EC50 ~μM |
Human/mouse; endothelial cells, VSMCs |
Aortic dissection |
Gi/o (↓cAMP), MAPK inhibition |
Level II–III |
Baclofen (GABAB agonist); CGP55845 (antagonist) |
GABBR2 is a subunit, not a standalone receptor; central nervous system effects |
[75,76] |
| Succinate |
SUCNR1/GPR91 |
Succinate EC50 ~20–50 μM |
Mouse/human; cardiomyocytes, juxtaglomerular cells, endothelium, immune cells |
HTN, MI/I/R, HFpEF, aortic dissection |
Gq (PLC–IP3–Ca2+); ERK1/2; JNK |
Level II |
cis-epoxysuccinate (agonist); NF-56-EJ40, compound 4c (antagonists) |
Context-dependent (pathological vs repair phase); tissue-specific effects |
[77,78,79,80,81,82,83,84,85,86,87,88,115,116,117,118] |
| β-hydroxybutyrate (BHB) |
HCAR2; FFAR3/GPR41 (antagonist) |
BHB EC50 ~100–700 μM (HCAR2); IC50 ~mM (FFAR3) |
Mouse/human; macrophages, cardiomyocytes, sympathetic neurons, chromaffin cells |
Atherosclerosis, HF, MI, vascular calcification |
HCAR2: Gi/o; FFAR3: antagonism of Gi/o |
Level II–III |
Niacin (HCAR2 agonist); AR420626 (FFAR3 agonist) |
High concentrations required; multiple receptor targets; NLRP3 inhibition is HCAR2-independent |
[90,91,92,93,94,95,96,97,98,99] |
| Lactate |
GPR132/G2A; HCAR1/GPR81 |
Lactate EC50 ~1–10 mM (GPR81); ~mM (GPR132) |
Mouse; macrophages, cardiomyocytes, endothelium |
Diabetes-accelerated atherosclerosis, MI, ischemia |
GPR132: Src; GPR81: Gi/o |
Level III–IV |
3,5-DHBA (GPR81 agonist) |
High physiological concentrations; GPR132 also senses oxidized phospholipids |
[100,101,102,103,104,105,106,107,108,109] |
| Adenosine |
ADORA1/A1; ADORA2A/A2A; ADORA2B/A2B; ADORA3/A3 |
Adenosine EC50 ~nM–μM (subtype-dependent) |
Human/mouse; cardiomyocytes, endothelium, VSMCs, immune cells |
Arrhythmia, MI, HF, vascular fibrosis |
A1/A3: Gi/o; A2A/A2B: Gs |
Level I (adenosine for SVT) |
Adenosine (non-selective); regadenoson (A2A agonist) |
Short half-life; subtype-specific opposing effects |
[110,111,112,113] |
| L-amino acids, polyamines |
CaSR |
L-Phe EC50 ~mM; Ca2+ EC50 ~mM |
Human/mouse; parathyroid, kidney, VSMCs, macrophages, cardiomyocytes |
Vascular calcification, PAH, HTN, myocardial remodeling |
Gq/Gi (PLC–IP3–Ca2+) |
Level II–III |
Cinacalcet (positive allosteric modulator); calcilytics (antagonists) |
Broad tissue expression; interference with calcium homeostasis |
[56,57,58,59,60,61,62,63] |